aTYR PHARMA INC
ATYR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001339970
No open-market purchases or sales by aTYR PHARMA INC insiders were filed in the last 90 days; 89 institutions reported holding it in 13F filings for Q2 2026, worth $23.2M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding aTYR PHARMA INC changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 41 | 36 | −5 |
| Shares | 19.6M | 18.8M | −859.3K (−4.4%) |
| Value | $105.0M | $53.1M | −$51.9M (−49.4%) |
New holders (5)
Institutions that held aTYR PHARMA INC at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 46,539 | $132.0K | 0.00% |
| Acadian Asset Management LLC | 19,963 | $57.0K | 0.00% |
| D.A. Davidson & Co. | 10,800 | $31.0K | 0.00% |
| Jane Street Group, LLC | 10,157 | $29.0K | 0.00% |
| Group One Trading, L.P. | 5,648 | $16.0K | 0.00% |
Sold out (10)
Institutions that held aTYR PHARMA INC at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Citadel Advisors LLC | 159,921 | $855.0K |
| Ikarian Capital, LLC | 37,017 | $197.0K |
| Wolverine Trading, LLC | 22,089 | $120.0K |
| D. E. Shaw & Co., Inc. | 18,808 | $101.0K |
| Ameriprise Financial Inc | 15,700 | $84.0K |
| ExodusPoint Capital Management, LP | 13,456 | $72.0K |
| Citigroup Inc | 650 | $3.00K |
| Raleigh Capital Management Inc. | 600 | $3.00K |
| Morgan Stanley | 72 | $0 |
| Cutler Group LP | 85 | $0 |